Safety and efficacy in ROSiA, a single-arm study of extended duration front-line (FL) bevacizumab (BEV)-containing therapy in 1021 women with ovarian cancer (OC)

Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPOZA, A. M.SELLE, F.DAVIDENKO, I.KORACH, J.MENDIOLA, C.GOCZE, P.PAUTIER, P.CHMIELOWSKA, E.BAMIAS, A.DECENSI, A.ZVIRBULE, Z.GONZALEZ-MARTIN, A.HEGG, R.JOLY, F.ZAMAGNI, C.GADDUCCI, A.DEURLOO, R.REVIL, C.ROBB, S.COLOMBO, N.2016-03-242016-03-242015EUROPEAN JOURNAL OF CANCER, v.51, suppl.3, p.S532-S532, 20150959-8049https://observatorio.fm.usp.br/handle/OPI/13752engrestrictedAccessSafety and efficacy in ROSiA, a single-arm study of extended duration front-line (FL) bevacizumab (BEV)-containing therapy in 1021 women with ovarian cancer (OC)conferenceObjectCopyright ELSEVIER SCI LTDOncology1879-0852